Shanghai Henlius Biotech Reports First Patient Dosing of Hansizhuang for Extensive-Stage Small Cell Lung Cancer Treatment in the US
Shots:
- The first patient was dosed in a bridging head-to-head study to evaluate the efficacy of Hansizhuang (serplulimab) vs atezolizumab in the US patient (n= 100) with ES-SCLC based on the positive feedback from the US FDA for BLA submission of Hansizhuang
- In Apr 2022, Hansizhuang received ODD from the US FDA and also NDA has been accepted by the NMPA for Hansizhuang + CT to treat 1L ES-SCLC
- In Mar 2022, Hansizhuang (a mAb) was launched in China for the treatment of MSI-H solid tumours and squamous non-small cell lung cancer
Ref: PRNewswire | Image: Henlius
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
